Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Phase 1, that's the ticket. My Two Cents
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by Scottyon Mar 10, 2021 9:04pm
209 Views
Post# 32769375

RE:RE:RE:RE:RE:RE:RE:RE:RE:Phase 1, that's the ticket. My Two Cents

RE:RE:RE:RE:RE:RE:RE:RE:RE:Phase 1, that's the ticket. My Two CentsLOL "multiple alias'", I'm sure you meant "multiple aliases", anyway I'm already out. I saw the dip around 10c and got out between 10 and 9.5 ish. Still lost a couple thousand overall since I sold most at a loss pre-halt. Had over 1.5m shares at one point back in the GVHD days.

You bulls are crazy, the level of dilution coming your way will be absolutely nuts, IDC how legit the science is, you're all getting robbed long term.

I plan to short this hard once they announce the RS and dilution, no brainer.

BTW I bash this company because it's a scam, I'm not a current short. Future short, not current short.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities